Targeting inflammation to treat diabetic kidney disease: the road to 2030

S Rayego-Mateos, RR Rodrigues-Diez… - Kidney international, 2023‏ - Elsevier
Diabetic kidney disease (DKD) is one of the fastest growing causes of chronic kidney
disease and associated morbidity and mortality. Preclinical research has demonstrated the …

[HTML][HTML] Chronic kidney disease-induced muscle atrophy: Molecular mechanisms and promising therapies

K Wang, Q Liu, M Tang, G Qi, C Qiu, Y Huang… - Biochemical …, 2023‏ - Elsevier
Chronic kidney disease (CKD) is a high-risk chronic catabolic disease due to its high
morbidity and mortality. CKD is accompanied by many complications, leading to a poor …

Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk

S Wilson, P Mone, SS Jankauskas… - The Journal of …, 2021‏ - pmc.ncbi.nlm.nih.gov
Chronic kidney disease is defined by the presence of kidney damage or decreased kidney
function for at least three months, irrespective of the cause. 2 Kidney damage generally …

Use of continuous glucose monitoring in the assessment and management of patients with diabetes and chronic kidney disease

J Ling, JKC Ng, JCN Chan, E Chow - Frontiers in endocrinology, 2022‏ - frontiersin.org
In developed countries, diabetes is the leading cause of chronic kidney disease (CKD) and
accounts for 50% of incidence of end stage kidney disease. Despite declining prevalence of …

Nutritional management in patients with chronic kidney disease: A focus on renal diet

H Hasan, MH Rahman, MA Haque… - Asia Pacific Journal of …, 2024‏ - apjmi.org
Chronic Kidney Disease (CKD) is a significant global health issue, contributing to high rates
of morbidity and mortality. Nutritional management, particularly through the implementation …

Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective …

A Yang, M Shi, ESH Lau, H Wu, X Zhang, B Fan… - …, 2023‏ - thelancet.com
Background Renin-angiotensin-system inhibitors (RASi), that include angiotensin converting
enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) reduce proteinuria …

[HTML][HTML] Broadening horizons in mechanisms, management, and treatment of diabetic kidney disease

A Petrazzuolo, G Sabiu, E Assi, A Maestroni… - Pharmacological …, 2023‏ - Elsevier
Diabetic kidney disease (DKD) is the first cause of end-stage kidney disease in patients with
diabetes and its prevalence is increasing worldwide. It encompasses histological alterations …

Clinical outcomes following discontinuation of metformin in patients with type 2 diabetes and advanced chronic kidney disease in Hong Kong: a territory-wide …

A Yang, M Shi, H Wu, ESH Lau, JTK Cheung… - …, 2024‏ - thelancet.com
Background Current labelling advises discontinuation of metformin when estimated
glomerular filtration rate (eGFR)< 30 ml/min/1.73 m 2 due to increased risk of lactic acidosis …

Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced …

JJ Chen, CY Wu, CC Jenq, TH Lee, CY Tsai… - JAMA Network …, 2022‏ - jamanetwork.com
Importance Glucagon-like peptide-1 (GLP-1) receptor agonist use is associated with
reduced mortality and improved cardiovascular outcomes in the general population with …

Effects of short-term potassium chloride supplementation in patients with CKD

M Gritter, RD Wouda, SMH Yeung… - Journal of the …, 2022‏ - journals.lww.com
Background Observational studies suggest that adequate dietary potassium intake (90–120
mmol/day) may be renoprotective, but the effects of increasing dietary potassium and the risk …